2022 Hybrid annual Meeting Program

FEATURE SESSIONS openness and transparency and increasing values necessary to foster and maintain the relevance of HTA recommendations by public confidence? ensuring they are informed by stakeholders. Despite many years of research to develop This plenary will explore the nature of public the field, in most jurisdictions its use and confidence and how it might influence impact in HTA is unclear, and its relationship how we reconceptualize HTA’s place to scientific rigor is unresolved. The in the lifecycle and our societies. It will task remains challenging. How should elicit different stakeholders’ experiences stakeholders’ perspectives be integrated of integrating perspectives in HTA and transparently? How can competing needs challenge the community to take a critical and claims be managed? Which types of view of HTA’s contribution to public stakeholders are not included and what are confidence in health and science. the consequences of this lack of inclusivity? What does public confidence look like, how MODERATOR should it be measured and to what extent can it be achieved? Ms. Heidi Livingstone Senior Public Involvement A lifecycle approach promises opportunities Adviser, Public Involvement to address the disconnect between Programme, NICE, United stakeholders, but may also increase the Kingdom number and diversity of stakeholders and their perspectives as HTA collaboration Heidi is a Senior crosses jurisdictions and assesses and Public Involvement Adviser in the Public reassesses value in different settings and Involvement Programme (PIP) in NICE. cultures. Amongst this potentially increased She moved to the Public Involvement diversity of world views, can shared values team in 2011 having joined NICE from be found to support public confidence? the Health Development Agency in What processes can support the continuous 2005 and had worked in the NHS since dialogue imagined among stakeholders 1997. She is responsible for patient and in a lifecycle approach? Will processes to public involvement in medicines Health integrate stakeholder perspectives support Technology Assessments work at NICE, wider confidence in procedural justice? specifically Technology Appraisals and Who will agree the priorities? How will Highly Specialised Technologies, and power differences be managed? has experience of working on Scientific Advice, Interventional Procedures, Medical Since its conception, HTA has invested Technologies and Diagnostics. Heidi works heavily in developing robust processes with individual patients, carers, lay people that can stand the test of scientific scrutiny and patient organisations who wish to get and peer review. But the pandemic has involved in the guidance, providing support, highlighted that scientific rigor is not training and advice. She has led on different synonymous with public confidence. service evaluations of patient participation Elements of the public, including some in the technology appraisal process at NICE stakeholders, may have no awareness or and provides training for patient groups as connection to the scientific principles, well as materials to help them participate processes, methods and institutions in NICE. She works with the Innovative esteemed in the HTA community. HTA may Licensing and Access Pathway (ILAP) be able to determine the value of health partner organisations (the Medicines and technologies from pre-market approval to Healthcare products Regulatory Agency, disinvestment, but can it find the shared the Scottish Medicines Consortium, the All 51

FEATURE SESSIONS Wales Therapeutics and &Toxicology Centre He is Chair of the HTAi Asia Policy Forum, and NICE) on patient involvement in ILAP. a past President of HTAi and a past Chair of INAHTA. Heidi is a member of the HTAi Patient and Citizens Involvement Group steering group SPEAKERS and works with colleagues internationally to improve patient involvement in HTAs, Ms. Linda Daniels-van particularly in medicines HTAs. She is Saase one of the contributing authors in Patient Manager Medisch- Involvement in Health Technology specialistische zorg, Assessment, Springer, 2017(http://www. Patiëntenfederatie springer.com/gb/book/9789811040672) Nederland, the as well as lead author on Evaluation of the Netherlands impact of patient input in health technology assessments at NICE (Cambridge University Mrs. Linda Daniels-van Saase is a Manager Press: 29 January 2021, e33). at the Netherlands Patients Federation which represents more than 200 patient Prof. Guy Maddern organizations. Mrs. Daniels-van Saase Surgical Director Research studied law and graduated in 1996 from the & Evaluation (RAAS), University of Amsterdam and has worked Australia at the Dutch Institute of Healthcare. In her previous role she was responsible Professor Guy Maddern for improving the quality of care and is the RP Jepson reimbursement packages for patients. Professor of Surgery at the University of Adelaide, Director of Research at the Basil Dr. Alicia Granados Hetzel Institute for Translational Health Head of Global Rare Research at The Queen Elizabeth Hospital Diseases Medical and Director and Surgical Research and Scientific Advocacy, Sanofi Evaluation (incorporating ASERNIP-S) Genzyme, Spain of the Royal Australasian College of Surgeons. He was trained at the University Dr. Granados has an MD of Adelaide and became a Fellow of the & Ph.D. in Public Health from the University Royal Australasian College of Surgeons in of Barcelona and is a specialist in respiratory 1989. He has also published widely on new medicine. She is currently serving as Head surgical techniques and their introduction of Global Rare Diseases Medical Scientific into surgical practice. He has over 600 Advocacy at Sanofi Genzyme, where she publications in scientific journals. has been heading its global HTA strategy since 2021 and the former President of the The evaluation of new technologies Scientific Advisory Committee of AQuAS and in particular surgical technologies is (Catalan Agency for Quality and HTA). another area of focus and interest. Under his supervision, ASERNIP-S has been Dr. Granados was responsible for creating responsible for assessing these technologies and directing the Catalan Agency for Health before exposing the Australian population Technology Assessment and Research to them and has provided this service to (CAHTAR). She was a founding member the Australian and International community of INAHTA, the first international HTA for over 20 years. It is recognized nationally network, and the first HTA joint initiative in and internationally as the premier surgical innovation assessment group. 52

FEATURE SESSIONS Europe, EUR-ASSESS, the predecessor of Osteba -Osasun ebaluazioa-, Basque Office EUnetHTA. She is also former President of for Health Technology Assessment. He is the International Society for Technology currently the coordinator of the EU funded Assessment in Health Care (ISTAHC) and project SAFENMEDTECH and coordinator Chair of the Committee for the Creation of of WP in the projects EXACT, INNO4COV, a new HTA Society: HTAi, of which she was CAREMATRIX and HARMONICS. He is the the first president. visiting director of HTA and Market Access at Health Cluster Network, performing Dr. Granados has been the temporary different functions. He has been technical advisor of several UN agencies on advisor of WHO on medical devices and Evidence-Based Health Care and Acting HTA and universal coverage and has advised Regional Advisor of the WHO European or lectured on HTA in countries such as: Office, leading the Health Evidence Costa Rica, Colombia, Malaysia, South Network. She has been an Associate Korea, Italy, Norway, Balkans Region, Egypt, Professor of Medicine at the University of Tunisia, Mexico, China, Ghana, Brazil, USA, Barcelona and has published more than 60 Argentina, Vietnam, Singapur, Taiwan, scientific and policy articles. Dr. Granados among others. He is associate editor is former President of the Autonomous of HiNT and Frontiers in Pharmacology University of Barcelona’s Board of Trustees, Journals and member of the editorial board Advisor to the Catalan Government at IJTAHC and Health Policy. President on wellness and economic reactivation and growth (CAREC), and the Dr. Claudia Wild Department of Health Advisory Council Managing Director of Catalan Government. She is currently (Geschäftsführung), HTA serving voluntarily as Chair of the HTAi Austria, Austria Policy Forum Series Advisory Committee. Dr. Claudia Wild is the Dr. Iñaki Gutiérrez- Chief Executive Officer Ibarluzea (CEO) of AIHTA GesmbH since 2020. Director of Innovation, Previously she was the Director of the BIOEF, Spain LBI-HTA since its establishment in 2006. From 1989-2006 she worked as a Senior Dr. Gutiérrez-Ibarluzea Researcher at the Institute of Technology has a BSc and MSc Assessment at the Austrian Academy of in Sciences from the University of the Sciences and helped develop the research Basque Country UPV-EHU, Doctor in field Health Technology Assessment in Sciences (NeuroScience) from the same Austria. She studied communications & university, Masters in Epidemiology from the psychology at the University of Vienna and Universidad de Granada and the Andalusian political sciences at the Ohio University School of Public Health and Masters in in Athens/Ohio/USA and completed her Bioethics from Blanquerna - Universitat studies with a Graduation at the University Ramon Llull and the Borja Vilaseca Institute of Vienna as a Doctor of Philosophy in of Bioethics. Past-President of HTAi (2021- 1985. In 2009, she habilitated in social 2023) and President (2019-2021). He is the medicine (Medical University Graz) on the current president of i-HTS - International topic of “resource allocation in health-care HealthTechScan, the Head of Knowledge systems.” Dr. Wild is a member of numerous Management and Evaluation of the Basque expert panels providing advice on health Foundation for Health Innovation and policy. Research (BIOEF), and coordinator of 53

FEATURE SESSIONS Tuesday, June 28 system. Her area of responsibility is to support priority setting and HTA, including Special Session: HTA and beyond capacity building and HTA in Challenging Times: institutionalization in Ukraine. Ukraine Experience in Ukraine sets an excellent example of a LMIC with a recent rapid HTA institutionalization 09:25 – 09:35, Beatrix along with the legislative introductions of Theatre (Ground Floor) mandatory HTA and development of MEA (Managed Entry Agreements). The war in Ukraine has challenged the country and the world continues to witness Besides her full time work at SAFEMed, the heroism of a nation trying to protect its Rabia is the current Vice President of homeland. HTAi (2021-2023) and has been an active member of HTAi for many years, serving on While the healthcare system in Ukraine has the Board of Directors as ex officio (2013- been under attack, the Ukrainian Ministry of 2014), Director (2014-2017) and re-elected Health continues to make enormous efforts Director (2017-2020). to provide healthcare to people in need. Dr. Oresta Piniazhko Since 2020, HTA has been mandatory for PhD, Director of HTA all medicine coverage decisions and HTA Department at State Expert is now well institutionalized in Ukraine. Centre of Ministry of Health, The war has challenged the function, but Ukraine the Department has shown resilience to continue working and supporting the health Oresta is an experienced expert in HTA, care decisions to be HTA-based despite the pharmaceutical policy and implementation ongoing war. practitioner. She holds a PhD degree in Pharmacoeconomics and is currently This short session will cover the challenges holding a position of Director of HTA the Ukrainian HTA function faces and how Department at the State Expert Center they are overcoming them. of the Ministry of Health of Ukraine, ensuring management and implementation Dr. Rabia Kahveci of the best international practices of Senior Technical Advisor HTA into health care system of Ukraine for Pharmaceutical Policy since February 2019. Being a dynamic and Governance, SAFEMed communicator, she is also a President of project, Ukraine Ukraine ISPOR Chapter since 2017 and before ISPOR Ukraine Students Network Rabia Kahveci is Senior (2015-2017). Oresta is visiting lecturer at Technical Advisor for Pharmaceutical The Institute of Business Education of Policy and Governance in the SAFEMed Vadym Hetman Kyiv National Economics project, in Kyiv Ukraine since October 2018. University, Danylo Halytskyi Lviv National SAFEMed project is a USAID funded and Medical University. MSH led project that supports Ukrainian government. SAFEMed applies health system strengthening best practices to create evidence-based interventions and strengthen Ukraine’s pharmaceutical 54

FEATURE SESSIONS Wednesday, June 29 Cliff’s recent work has involved such areas as chronic disease, infectious disease, David Banta Tribute and cancer, rare diseases, diagnostic testing, Distinguished Career pharmacogenomics, gene therapy, Award Presentation biosimilars, value frameworks, value-based contracting, social determinants of health, 08:45 – 09:15, Beatrix and applications of real-world data. Since Theatre (Ground Floor) 2012, he has directed a major project to support the development and updating of We’d love to hear from you and include evidence-based clinical practice guidelines your recollections in a memory book to be using the rigorous GRADE methodology collated and bound following the Annual for the U.S. Veterans Health Administration Meeting. and Department of Defense, including more than 40 original and updated guidelines Put your memories and thoughts on paper on 24 diverse clinical topics, including in for us to share after the meeting. In-person chronic disease, mental and behavioral - visit booth 18 in Expo Hall or virtually. health, pain management, women’s health, rehabilitation, and military-related AWARD PRESENTER: conditions. Dr. Wija Oortwijn, the Netherlands A founding member of HTAi, Cliff has served on its Board, as its president (2011- 2022 DAVID BANTA 13), and on numerous committees for DISTINGUISHED CAREER many years through the present. Cliff has AWARD RECIPIENT: attended all annual meetings of HTAi and Dr. Clifford Goodman the predecessor society, ISTAHC, since their inception. Since the 1990s, he has Clifford Goodman, PhD, presented the introductory course, HTA is a Senior Vice President 101, to hundreds of attendees of annual at The Lewin Group, a health care policy meetings of ISTAHC and HTAi. consulting firm based in the Washington, DC, metropolitan area. The Lewin Group He served as Chair of the Medicare is a unit of Optum, a major subsidiary of Evidence Development & Coverage UnitedHealth Group. Advisory Committee (MEDCAC) for the U.S. Centers for Medicare and Medicaid Cliff has more than 30 years of experience Services (2009-2012). He is a Fellow of in such areas as health technology the American Institute for Medical and assessment, evidence-based health care, Biological Engineering (AIMBE). comparative effectiveness research, clinical practice guidelines, health economics, Cliff is an internationally recognized health and studies pertaining to health care policy issues moderator and facilitator of innovation, regulation, access, and symposia, expert panels, advisory boards, payment. He directs studies and projects and focus groups, having conducted for an international range of government hundreds of such events in recent years. agencies; pharmaceutical, biotechnology, and medical device companies; health Cliff earned a PhD from The Wharton care provider institutions; and professional, School of the University of Pennsylvania, industry, and patient advocacy groups. a Master of Science from The Georgia Institute of Technology, and a Bachelor of Arts from Cornell University. 55

FEATURE SESSIONS Wednesday, June 29 plenary, specific disease areas in which the collaboration on the collection and Plenary 3 analyzing of data may be flourishing such as cardiology, oncology (ATMPs 11:10 – 12:45, Beatrix Theatre such as CAR-T) and rare diseases, maybe (Ground Floor) highlighted. Further, emphasis may be placed on therapies approved through Running Around in Circles; accelerated regulatory processes or with Time for Real Collaboration coverage with evidence development between Regulators, HTA requirements. Bodies and Clinicians The following topics will be specifically Regulators, HTA bodies/payers but also addressed in the plenary: clinicians and their guideline organizations, may provide recommendations regarding 1. How are different types of (cost-)effectiveness of health technologies effectiveness evidence perceived by that have a large influence on the access to regulators, HTA bodies/payers and these technologies. Their recommendations clinicians over the lifecycle of health may not always closely align which might technologies? lead to hampered and delayed access to these health technologies and uncertainty 2. What are experiences in terms of for patients. However, the remit of those interaction between regulators, HTA organizations may vary to a large extent bodies/payers and clinicians and over the lifecycle of a health technology. To how could these be implemented what extent do we wish for more alignment for different types of health of their recommendations, for instance, technologies such as medical if the same data are used to evaluate devices and pharmaceuticals? clinical effectiveness? Or do we value the different roles of those stakeholders to 3. How do other stakeholders such as ensure a cautious balance between quality, innovators and patients perceive this affordability, and accessibility of healthcare? interaction between regulators, HTA How do innovators that develop new health bodies/payers and clinicians, what technologies experience these different is in it for them in different settings roles of those stakeholders and see their around the globe? differences as barriers or enablers for their innovations to come to patients? This third plenary will explore the impact of regulators, HTA bodies and clinicians This plenary will also include a discussion on on the quality and efficiency of healthcare the role of clinical practice data to improve by focusing on their clearly laid out roles, our knowledge on the effectiveness and their interaction and alignment of their cost-effectiveness of health technologies, processes. It will use the experiences such as pharmaceuticals, medical devices, of innovators and patients to assess and digital health (including AI) and how this impact and the interaction of these different types of data and evidence regulators, HTA bodies and clinicians. can be efficiently collected, used, and shared between those stakeholders at the different stages of the lifecycle. In the 56

FEATURE SESSIONS MODERATOR Dr. Arlett is the Head of the Data Analytics and Methods Task Force (March 2020 – Dr. Laura Sampietro- present). Previously, he was the Head of Colom Pharmacovigilance and Epidemiology VP HTA & Access Policy, Department, European Medicines Agency Johnson & Johnson, UK (2013–2020), Head of Pharmacovigilance and Risk Management Sector, European Dr Laura Sampietro- Medicines Agency (2008-2013, Principal Colom is the Deputy Director of Innovation Administrator, Pharmaceuticals Unit, and Head of the Health Technology European Commission (2003-2008), UK Assessment (HTA) Unit at the Hospital delegate to the European Committee for Clinic of Barcelona, a high-tech hospital Human Medicinal Products (CHMP) (2001- and a reference for health care, research, 2003), Specialist Assessor and Manager, innovation and medical training in Spain. In Medicines Control Agency (now MHRA) her everyday work she supports clinicians (1996-2001) and Hospital Physician, UK to prove the value for their clinical practice NHS: UCL, Oxford, Hammersmith (to 1996). of both health care technologies they are developing and new technologies In addition to his medical degree from candidate to be introduced in the Hospital. University College London (UCL) (1991), She is also active in different national and Dr. Arlett has been a member of the international initiatives around Innovative Royal College of Physicians (MRCP) of Public Procurement. She is member of London (1994), a fellow of the Faculty of the advisory board of the EIT Health High Pharmaceutical Medicine (FFPM) of the Value Care Forum. She was the Project Royal College of Physicians of London Leader of the EU Project Adopting Hospital (2007), a fellow of the Royal College of based Health Technology Assessment Physicians of Edinburg (2017) and honorary (AdHopHTA; 7th Framework Program). She Professor, London School of Hygiene and was President of the International Society Tropic Medicine (2020 for HTA (HTAi) and Chair of its Global Policy Forum and founder and Chair of the Latam Professor Alan Fraser Policy Forum. She was one of the founders, Consultant Cardiologist and scientist, of the Catalan Agency for and Scientific Coordinator Health Technology Assessment (nowadays CORE-MD, University AQuAS). During all these years, her work has Hospital Wales, United focused on the development, identification, Kingdom management and transfer of information to advise, public and private organizations, Dr. Alan Fraser is a on designing strategies and policies for Consultant Cardiologist at the University developing and adopting innovative Hospital of Wales, Cardiff, UK; Visiting technologies. Professor in Cardiovascular Imaging and Dynamics at the University of Leuven, SPEAKERS Belgium; and Emeritus Professor of Cardiology at the Wales Heart Research Dr. Peter Arlett Institute, Cardiff University. He is a Past- Head, Data Analytics President of the European Association & Methods, European of Cardiovascular Imaging. He chairs Medicines Agency, the the Regulatory Affairs Committee of the Netherlands Biomedical Alliance in Europe and is the 57

FEATURE SESSIONS Scientific Coordinator of the EU Horizon As Director of Research for global health 2020 CORE-MD project (Coordinating non-governmental organizations in the Research and Evidence for high-risk Medical United Kingdom and Australia, he managed Devices). His research interests include portfolios of health consulting and research cardiac imaging, heart valve disease, heart projects focusing on pharmaceutical policy, muscle disease, and the pathophysiology pharmaceutical systems strengthening, and and diagnosis of heart failure. diseases that disproportionately affect low- and middle-income countries. Dr. Javier Guzman Director, Global Health In addition to his medical degree, Javier Policy, Center for Global has an MSc in Health Policy, Planning and Development, Colombia Financing from the London School of Economics and Political Science and the Javier Guzman is the London School of Hygiene and Tropical Director of Global Health Medicine and an MBA (Executive) from the Policy and a Senior Policy Fellow at the Australian Graduate School of Management. Center for Global Development. Previously, he was the Technical Director of the USAID- Professor Eva Havrdova funded Medicines, Technologies, and Department of Neurology Pharmaceutical Services (MTaPS) Program and Center for Clinical at Management Sciences for Health (MSH), Neuroscience, Charles helping over 20 governments in Africa and University, Czech Republic Asia build their health system to ensure sustainable access to and appropriate use Dr Eva Kubala Havrdova is of safe, effective, quality-assured, and Professor of Neurology at the First Faculty affordable medicines and pharmaceutical of Medicine, General University Hospital, services. Between 2013 and 2018, he Charles University in Prague, Czech played different roles within the Colombian Republic. government, first as Deputy Director of the health technology assessment agency, She obtained her medical degree at the then as Director of Medicines and Health same university in 1981 and went on Technologies at the Ministry of Health to specialize in neurology and became and finally, as Director-General of the Professor at Charles University in 2010. Colombian Food and Drug Surveillance She is currently Director of the Center Institute, one of the eight National for Demyelinating Diseases at Charles Regulatory Authorities of regional reference University, Prague. in the Americas. Dr Kubala Havrdová’s research interests Javier has worked as a physician, researcher, include cytokine, immunoglobulin & analyst and policymaker in the United T-cell research in multiple sclerosis, States, the United Kingdom, Australia, and treatment of malignant MS. She created his native Colombia. He is interested in how “freedom from disease activity” concept global health challenges such as Covid and used now to compare efficacy of MS antimicrobial resistance, can offer a window drugs. She has published more than 150 of opportunity to improve the efficiency publications on multiple sclerosis including and effectiveness of global institutions and Neuroimmunology, Multiple Sclerosis, build more sustainable and equitable health Handbook on MS for General Practitioners, systems. Pharmacotherapy of MS, and several books for patients. 58

FEATURE SESSIONS She organized ECTRIMS Congress in Mrs. Ivett Jakab Prague in 2007, is a member of MSIF Patient advocate, EUPATI International Medical and Scientific Board, Fellow, Hungary and member of the Czech Neurological Society Committee. She introduced She has been volunteering disease modifying treatment in MS in for local patient Czech Republic and established a network organizations in the field of MS Centers covering all the country. of organ transplantation She developed Standards of Diagnostics since 2011. She graduated from the and Treatment of MS and NMO in Czech European Patients’ Forum (EPF) Summer Republic. Training for Young Patient Advocates (STYPA) program in 2018 and supported the Professor Dana Horakova 2019 edition as a team leader. She joined Dept. of Neurology the EPF Youth Group in 2019 and lead and Center for Clinical the group as President until 2022 working Neuroscience, Czech to strengthen the young patients’ voice Republic throughout Europe. She is a EUPATI Fellow who graduated in 2021 and a member of Prof. Dana Horakova, MD, the EUPATI Board of Trustees. Her research graduated from the Faculty of Medicine interests are in the evolving areas of HTA of Charles University in 1992. Since 1999 and patient engagement in healthcare she has worked at the MS Centre of the 1st decision-making. Her mission is to bring Faculty of Medicine of Charles University the perspectives of different stakeholders in in Prague. In 2006 she completed a six- healthcare closer together. month internship at BNAC in Buffalo, USA. In 2010 she received her Ph.D. degree with Ivett is a patient herself; she had an acute the thesis “Predictive markers for clinical liver transplant in 2008 due to a rare genetic development in MS patients.” disorder called Wilson’s disease. Dr. Horakova is a member of the Dr. Christine Muzel Immunology Committee of the Czech Director, Technology Neurological Society and serves as a Strategy, Philips, Belgium scientific guarantor of the Czech national ReMuS registry. She was the Chair of the Mrs. Muzel leads the MSBase Scientific Leadership Group from integration of health 2014 to 2020 and is currently a member economics and market of the SLG and a member of the MSBase access strategies into the innovation- Advisory Board. to-market process, with a focus on the evidence necessary to prove value to Her key research interests include - markers providers, payers, patients, and health of disease activity and treatment response technology assessment bodies in the rapidly (clinical and MRI, especially implementation changing landscape of health care. and validation of quantitative volumetric MRI techniques into routine clinical practice) and She brings extensive international the use of databases and registries in MS. experience in Medtech start-ups, business ventures and global corporations, spanning technology and go-to-market strategy, product management, sales, market access 59

FEATURE SESSIONS and reimbursement for innovative health academia and government. In 2004 technologies. he was awarded an Atlantic Fellowship from the British Government and chose She holds an M.A. in business studies and to serve as Senior Fellow at the National humanities, a diploma in health economics, Institute for Health and Clinical Excellence and an Executive MBA in Healthcare (NICE). Returning to the United States in Management, Financing and Policy, with a 2005 he was asked to serve during the focus on value-based healthcare and health George W. Bush Administration as Special system strengthening. Advisor, Technology and Coverage Policy, at the Centers for Medicare and Medicaid Dr. Steven Pearson Services, and also accepted an appointment President, ICER, United as Visiting Scientist in the Department States of Bioethics at the National Institutes of Health, a position he maintained from Steven D. Pearson, MD, 2005-2019. In other roles, Dr. Pearson MSc is the Founder has also served as the Vice Chair of the and President of the Medicare Evidence Development and Institute for Clinical and Economic Review Coverage Advisory Committee (MedCAC). (ICER). Dr. Pearson is also a Lecturer in the Department of Population Medicine at Dr. Pearson’s publications include over 150 Harvard Medical School. peer-reviewed articles and commentaries on the role of evidence in the health care An internist, health services researcher, system, and the book No Margin, No and ethicist, Dr. Pearson has served in Mission: Health Care Organizations and the many advisory and leadership roles in Quest for Ethical Excellence, published by Oxford University Press. 60

FEATURE SESSIONS Wednesday, June 29 This year, HTAi awarded a total of 42 Participation Grants to 13 patients and Closing Ceremony and patient representatives, 23 residents of lower Presentation of Awards or middle-income countries, and 6 students. 12:45 – 14:00, Beatrix We would like to thank our Participation Theatre (Ground Floor) Grant Sponsors for their generous support. HTAi ANNUAL MEETING JILL SANDERS MEMORIAL PRESENTATON AWARDS SCHOLARSHIP AWARD • Best Oral Presentation Award Presenter: • Best Student Oral Presentation • Rabia Kahveci, Ukraine • B est Poster • Best Student Poster HTAI EDUCATIONAL Award Presenters: SCHOLARSHIP AWARD • Dr. Wim Goettsch, Netherlands • Ms. Ann Single, Australia Award Presenter: • Professor Gert Jan van der Wilt, • Rabia Kahveci, Ukraine Netherlands SIGRID DROSTE ETHICS AWARD INTERNATIONAL JOURNAL OF TECHNOLOGY Award Presenter: ASSESSMENT IN HEALTH • Dr. Alric Rüther, Germany CARE (IJTAHC) AWARDS Introduction to HTAi 2023 EGON JONSSON AWARD Annual Meeting, in Adelaide, Foreword from Professor Egon Jonsson Australia, June 23 to 28, 2023 Award Presenter: • Professor Brendon Kearney, Australia • Wija Oortwijn, Netherlands • Professor Guy Maddern, Australia BEST REVIEWER AWARD Closing Remarks Award Presenter: • Dr. Wija Oortwijn, HTAi President, • Wendy Babidge, Australia Netherlands 61

Online MSc Health Technology Assessment Want to be a 21st century HTA practitioner? Students can study to Certificate, Diploma or Masters Governments around the world are increasingly using (includes a research project) level. Health Technology Assessment (HTA) to inform decision- For more details please visit making. Join our online distance learning programme www.gla.ac.uk/hta and enhance your career by acquiring quantitative and qualitative research skills in support of HTA. Continuous Professional Development (CPD) The course is taught via video presentations by teaching Our CPD programme includes our new live, online course faculty, live online lectures, weekly exercises, directed Maximising the Value of Clinical Trial Data: Advanced readings and student/faculty interaction on discussion Analysis for Economic Evaluation and Modelling. In forums. addition, the online MSc HTA courses listed above can be taken as non-accredited CPD. They run at the same time Our MSc comprises three core courses: as the MSc courses so please visit • HTA: Policy and Principles www.gla.ac.uk/hta for more details of dates. • Statistical Methods for HTA and Evidence-Based Medicine Contact us: • Health Economics for HTA • Research Project Health Economics and Health Technology (core ‘course’ only for MSc level) Assessment (HEHTA) 1 Lilybank Gardens, Glasgow G12 8RZ Students may then select from a range of optional Tel: +44 (0)141 330 4010 courses: Website: www.gla.ac.uk/hehta Twitter: @HEHTAGlasgow • Outcome Measurement and Valuation for HTA LinkedIn: www.LinkedIn.com/company/hehta • Qualitative Research Methods for HTA • HTA in a Global Context • Survival Analysis for HTA • Decision Analytical Modelling and Early HTA • Data Science • Evidence Synthesis • Choice Experiments for Health Economics • Maximising the Value of Clinical Trial Data: Advanced Analysis for Economic Evaluation and Modelling © University of Glasgow 2022. The University of Glasgow, charity number SC004401 27/05/2022 09:28 HEHTA Online Health Technology Advert.indd 1 62

Workshops

WORKSHOPS Workshops WS05 HTA 101: Introduction to Health Technology Assessment Saturday, June 25 2022 08:30 - 12:00, Room 315 WS01 Advanced Workshop in Information Retrieval: Addressing Cliff Goodman, USA Lifecycles of the Literature in Health Technology Assessment WS18 Lifecycle Approach to Regulatory, Management and Assessment of Health 08:30 - 12:00 & 13:00 - 16:00, Room Technologies: Is it the Solution for 114 Resource Constraint Settings? Christa Niehot, Netherlands 13:00 - 16:30, Room 215 Mbachi Ruth Msomphora, Norway Per-Olov Andersson, Sweden Jani Mueller, South Africa James Thomas, UK Joseph T Matthew, India Siw Waffenschmidt, Germany Amanda Hodgson, Canada WS18 Lifecycle Approach to Regulatory, Monika Mierzwinski-Urban, Canada Management and Assessment of Health David Kaunelis, Canada Technologies: Is it the Solution for Stacy Brody, USA Resource Constraint Settings? Nicole Askin, Canada Mark Mueller, Canada 13:00 - 16:30, Room 215 Ingrid Harboe, Norway Jani Mueller, South Africa WS02 How to Incorporate Joseph T Matthew, India Environmental Impact to Quality of Care and Guidelines WS06 An Interactive Workshop on the Theory and Practice of Measuring 08:30 - 12:00, Room 117 the Impact of Health Technology Assessment Ayla Lokhorst, Netherlands Pauline de Heer, Netherlands 13:00 - 16:30, Room 315 Iris Wichers, Netherlands Matthias Perleth, Germany WS03 How to Perform a Trial-Based Chantal Guilhaume, France Economic Evaluation Using R Jeff Round, Canada Catherine Truchon, Canada 08:30 - 12:00, Room 215 Patrice Chalon, Belgium Johanna Van Dongen, Netherlands Judith Bosmans, Netherlands Angela Jornada Ben, Netherlands Mohamed El Alili, Netherlands 64

WORKSHOPS WS07 Generating and Using Real Sunday, June 26, 2022 World Evidence for Health Technology Assessment WS10 Research Oriented Market Access for Adopting High Cost Therapies – 13:00 - 16:30, Room 417 Principles and Practice Massoud Toussi, France 08:30 - 12:00, Room 315 Elena Petelos, Netherlands Dimitra Lingri, Greece Jeff Round, Canada Erin Kirwin, Canada WS08 Integrating Patient and Citizen Ken Bond, Canada Perspectives: Resources and Challenges for a Lifecycle Approach WS11 Early Awareness and Alert Systems (EAA) on New, Emerging and Obsolete 13:00 - 16:30, Room 117 Technologies Ann Single, Australia 08:30 - 12:00, Room 110 Niel Bertelsen, Germany Anke Holtorf, Switzerland Iñaki Gutierrez-ibarluzea, Spain Hedi Livingston, Netherlands Rosmin Esmail, Canada Aline Silva, Canada Maximilian Otte, Germany Hans-Peter Dauben, Germany Brendon Kearney, Australia Anne-Lien Espeland, Norway WS12 Values In Doing Assessments Of Healthcare Technologies (VALIDATE) 08:30 - 12:00, Room 117 Gert Jan van der Wilt, Netherlands Faye Freriks, Netherlands Payam Abrishami, Netherlands Ann Single, Australia Bart Bloemen, Netherlands 65

WORKSHOPS WS13 An Introduction To Early Health WS15 Introduction to Ethics in Health Technology Assessment Technology Assessment 08:30 - 12:00, Room 215 13:00 - 16:30, Room 110 Janneke Grutters, Netherlands Duncan Steele, Canada Marcia Tummers, Netherlands Dario Sacchini, Italy Geert Frederix, Netherlands Gert Jan van der Wilt, Netherlands Kari Kværner, Norway Bart Bloemen, Netherlands Linn Støme, Norway Lars Sandman, Sweden Ken Bond, Canada WS09 HTA 102. Hospital-Based HTA WS16 Reducing the Computational 08:30 - 12:00 & 13:00 - 16:00, Room Burden of Health Economic Models and 114 Analyses Using Metamodeling Marco Marchetti, Italy 13:00 - 16:30, Room 215 Laura Sampietro-Colom, Spain Rossella Di Bidino, Italy Koen Degeling, Netherlands Kristian Kidholm, Denmark Hendrik Koffijberg, Netherlands Americo Cicchetti, Italy WS17 The Use of Evidence-Informed WS14 Exploring Methods for Deliberative Processes for Health Evaluating Impact of Patient and Public Technology Assessment in Low and Involvement in the Assessment of Middle Income Countries Technologies Along their Lifecycle 13:00 - 16:30, Room 117 13:00 - 16:30, Room 315 Wija Oortwijn, Netherlands Anke-Peggy Holtorf, Switzerland Rob Baltussen, Netherlands Ann Single, Australia Leon Bijlmakers, Netherlands Ana Toledo Chávarri, Spain Richmond Owusu, Ghana Lidewij Eva Vat, Netherlands Maryam Huda, Pakistan Sophie Staniszewska, United Kingdom Lyazzat Kosherbayeva, Kazakhstan Veronica Lopez Gousset, France Aline Silveira Silva, Canada 66

Panels

PANELS Panels PN04 Horizon Scanning for New and Emerging Technologies. Experiences Monday, June 27, 2022 Along the World, so Similar, so Different PN01 Building Bridges Between 14:20 - 15:35, Room 315 Patient and Treatment - Perspectives On Harmonizing Health Technology Iñaki Gutierrez-Ibarluzea Assessment with Up and Down-Stream Hans-Peter Dauben Stakeholders Izzuna-Mudla Mohamed Ghazali Dawn Craig 14:20 - 15:35, Room 114 PN05 Developing HTA in the Balkans - A Milou Hogervorst, Netherlands Road map for Success with International Mathias Møllebæk, Denmark Collaboration François Houÿez, France Dana Horáková, Czech Republic 14:20 - 15:35, Room Virtual Nick Crabb, United Kingdom Xavier Kurz, Netherlands Sarah Garner, Netherlands Aljosa Djudurovi, Bosnia and PN02 Health Technology Assessment in Herzegovina Situations of Uncertainty: The Case of Spela Zerovnik, Slovenia COVID-19 PN06 A Lifecycle Approach to Promote 14:20 - 15:35, Room 117 Engagement and Efficiency in HTA: 2022 HTAi Global Policy Forum Summary Diana Delnoij, Netherlands Dalia Dawoud, United Kingdom 14:20 - 15:35, Room Beatrix Theatre Jamie Elvidge, United Kingdom Harald Miedema, Netherlands Dan Ollendorf, United States Juan Carlos Réjon-Parrilla, Spain Rebecca Trowman, Australia Herve Nabarette, France PN03 The Year of Change: From Rick Vreman, Netherlands National to European Health Technology Susan Myles, United Kingdom Assessment Procedures Linetta Koppert, Netherlands 14:20 - 15:35, Room 417 PN07 Working Together in Health Technology Assessment on Oncology Zoe Garrett, United Kingdom Immunotherapy Lifecycle: Opportunities Alric Rüther, Germany and Challenges in East Asia 14:20 - 15:35, Room Virtual Yingyao Chen, China Jeonghoon Ahn, South Korea Ruoyan Gai, Japan Lizheng Shi, United States 68

PANELS PN08 Expedited Pathways for Drug PN12 Would the Novel Elements of Approval: Aligning Regulators, HTA Value Contribute to Equitable Access Agencies, Payers, Patients, Clinicians and to New Medical Technologies? - A Industry Multistakeholder Perspective 14:20 - 15:35, Room 215 17:15 - 18:30, Room 315 Sean Tunis, United States Wim Goettsch, Netherlands Nikas Hedberg, Sweden Ramiro Gilardino, United States Bettina Ryll, Sweden Valentina Strammiello, Belgium Chris Henshall, United Kingdom Andrew Bruce, Australia PN13 Deep Dive on Uncertainty - A Multistakeholder Discussion Hosted by PN09 The International Horizon the HTAi-DIA Joint Working Group Scanning Initiative: Empowering Governments to Identify and Negotiate 17:15 - 18:30, Room 417 Fair Prices for Innovative Health Technologies Inka Heikkinen, Denmark Wija Oortwijn, Netherlands 17:15 - 18:30, Room 114 Milou Hogervorst, Netherlands Iñaki Gutierrez-Ibarluzea, Spain Diana Delnoij, Netherlands Neil Bertelsen, Germany Marcus Guardian, Netherlands Dimitra Lingri, Greece Niels Speksnijder, Netherlands Sari Susanna Ormstad, Norway PN14 Deliberative Processes for Informed Decision - Making by Health PN10 From Thought to Action: Technology Assessment: HTAi Latin Legitimate Decision Making and the Role America Policy Forum 2021 Findings of Stakeholders in the HTA Processes 17:15 - 18:30, Room Beatrix Theatre 17:15 - 18:30, Room Virtual Manuel Espinoza, Chile Zinaida Bezverhni, Moldova Andres Pichon-Riviere, Argentina Gavin Surgey, Netherlands Vania Canuto, Brazil Augustina Koduah, Ghana Alicia Granados, Spain Rob Baltussen, Netherlands PN11 Can Social Media Research Help to Improve Public Confidence in Health Technology Assessment (HTA) and Healthcare Decision Making? 17:15 - 18:30, Room 215 Anke-Peggy Holtorf, Switzerland Joey Mattingly, United States Li-Ying (Grace) Huang, Taiwan Alissa Hanna, United States Aline Silveira Silva, Canada 69

PANELS PN15 Patient and Public Participation Tuesday, June 28, 2022 in Health Technology Assessment’s Organization Domain: Approaches and PN17 Fit for Purpose Novel Payment Opportunities Models to Increase Patient Access to Cell and Gene Therapies: Let’s Work 17:15 - 18:30, Room 117 Together Ann Single, Australia 11:35 - 12:50, Room Virtual Hervé Nabarette, France Isabelle Ganache, Canada Renske ten Ham, Netherlands Irina Cleemput, Belgium Simon Walker, United Kingdom Jurgen Kuball, Netherlands PN16 Impact of Health Policies on HTA Olivia Wu, United Kingdom Declan Noone, Belgium 17:15 - 18:30, Room Virtual PN18 Real-World Evidence’s Role in Karen Facey, United States Lifecycle Management: Learnings from Nicole Mitmann, Canada ICER and NICE’s Demonstration Projects Herve Nabarette, France Sheela Upadhyaya, United Kingdom 11:35 - 12:50, Room 117 Jo-anne Watson, Australia Ashley Jaksa, United States Jon Campbell, United States Seamus Kent, United States Riad Dirani, United States PN19 Journal Submissions - Some Useful Tips for Success 11:35 - 12:50, Room 215 Wendy Babidge, Australia Wim Goettsch, Netherlands Jani Mueller, South Africa Joseph Mathew, India PN20 Developing a Multi-Stakeholder Shared Learning Platform to Improve Understanding in the Use and Acceptance of RWE 11:35 - 12:50, Room 315 Deven Chauhan, United Kingdom Felix Greaves, United Kingdom Bettina Ryll, Sweden Shahid Hanif, Canada 70

PANELS PN21 Joint Scientific Consultations: PN25 Enhancing ‘Public Confidence in How Will the Present Inform the Future? Healthcare Decision-Making’ in Low- and Middle-Income Countries Through 11:35 - 12:50, Room 417 Stakeholder- and Context-Conscious Health Technology Assessment (HTA) Anne Willemsen, Netherlands Antje Behring, Germany 16:55 - 18:10, Room 114 Anja Schiel, Norway Claudine Sapede, Switzerland Jani B. Muller, South Africa Susanne Teupen, Germany Anke-Peggy Holtorf, Switzerland Lauren Pretorius, South Africa PN22 The Added Value of a Value- Narendra Javadekar, India Oriented Perspective in Health Izzuna Mudla Mohamed Ghazali, Technology Assessment Malaysia 11:35 - 12:50, Room 114 PN26 How may the Lifecycle Approach feed into HTA Capacity Building Bart Bloemen, Netherlands Strategies in Low- and Middle-Income Carla Fernandez Barceló, Spain Countries (LMICs)? Faye Freriks, Netherlands Joan Escarrabill, Spain 16:55 - 18:10, Room Virtual PN23 A Lifecycle Approach in Assessing Sharif Qaddomi, Palestine Digital Applications: In Silos or Teaming Richmond Owusu, Ghana Up Internationally? Katrine Frønsdal, Norway Sarah Garner, Netherlands 11:35 - 12:50, Room Beatrix Theatre Lieke Heupink, Norway Laura Sampietro-colom, Spain PN27 Sustainable Modeling: Taking Marcia Tummers, Netherlands a Lifecycle Approach to Model Kristian Kidholm, Denmark Development to Increase Assessment Jeanette Kusel, United States Efficiency and Validity Cristina Bescos, Spain 16:55 - 18:10, Room 215 PN24 Applying Patient Preferences in HTA: Do Preferences and Can Hendrik Koffijberg, Netherlands Preferences Influence HTA Decision Marjan Hummel, Netherlands Making? Mohamed El Alili, Netherlands Koen Degeling, Australia 11:35 - 12:50, Room Virtual Saskia Knies, Netherlands Deborah Marshall, Canada \\ Simon Fifer, Australia Barry Stein, Canada Barry Liden, United States 71

PANELS PN28 EU HTA Regulation: Improved PN32 Do Differences in HTA Deliberative Access or Layering of Processes? Structures Affect Confidence in the Outputs? A Discussion and Proposed 16:55 - 18:10, Room 315 Research Agenda Dima Samaha, United Kingdom 16:55 - 18:10, Room 117 Anne Willemsen, Netherlands Sara Lopes, Brazil Daniel Ollendorf, United States Mihai Rotaru, Belgium Ken Bond, Canada Sheela Upadhyaya, United Kingdom PN29 Patient Registries Providing Real- Jacqueline Zwaap, Netherlands World Evidence to Support a Lifecycle Evelyn Thsehla, South Africa Approach for HTA of Expensive Drugs, from Different Perspectives (COI) Wednesday, June 29, 2022 16:55 - 18:10, Room 417 PN33 Patient Involvement in Health Technology Assessment (HTA) – Are We Dorien Lobbezoo, Netherlands All on the Same Page? Wim Goettsch, Netherlands Mariëtte Driessens, Netherlands 09:25 - 10:40, Room 315 Daphne Schoenmakers, Netherlands Anke-Peggy Holtrof, Switzerland PN30 HTA in Asia Post-COVID-19: HTAi Niel Bertelsen, Germany Asia Policy Forum 2021 Findings Maria Dutarte, Netherlands Lonneke Timmers, Netherlands 16:55 - 18:10, Room Beatrix Theatre Hannes Jarke, Belgium TBD PN34 Creating Political, Societal and Professional Support for Sustainable PN31 Regulatory and Health Technology Healthcare Choices Assessment Alignment: A Match Made in Heaven or Irreconcilable Differences? 09:25 - 10:40, Room Beatrix Theatre 16:55 - 18:10, Room Virtual Diana Delnoij, Netherlands Gijsbert Werner, Netherlands Jacoline Bouvy, United Kingdom Sarah Kleijnen, Netherlands Anja Schiel, Norway Meindert Boysen, United Kingdom Bettina Ryll, Sweden Patrick Jeurissen, Netherlands Huseyin Naci, United Kingdom Sjaak Wijma, Netherlands 72

PANELS PN35 Qualitative Evidence: A PN38 Outcome-Based Reimbursement Methodology That Can Guide Lifecycle and Delayed-payment Schemes for Health Technology Assessment New Technologies Central and Eastern European and Middle Eastern Countries 09:25 - 10:40, Room 417 09:25 - 10:40, Room 215 Alessandra Lo Scalzo, Italy Karen Macpherson, United Kingdom Marcelien Callenbach, Netherlands Sophie Söderholm Werkö, Sweden Ildiko Ádám, Hungary Iñaki Gutierrez-Ibarluzea, Spain Rabia Kahveci, Turkey Deirdre DeJean, Canada Iga Lipska, Poland Wim Goettsch, Netherlands PN36 Beyond Checking the Boxes: Guidance Of The Joint HTAi – ISPOR PN39 A Lifecycle Approach to HTA: Task Force Deliberative Processes for The Role of Implementation Alongside HTA Economic Evaluation 09:25 - 10:40, Room 114 09:25 - 10:40, Room Virtual Wija Oortwijn, Netherlands Robert Heggie, United Kingdom Don Husereau, Canada Ties Hoomans, United Kingdom Jacqueline Zwaap, Netherlands Simon Walker, United Kingdom Li-Ying (Grace) Huang, Taiwan Caroline Clarke, United Kingdom Vania Canuto, Brazil Edward Clifton, United Kingdom PN37 Collaboration to Overcome PN40 Value From a Multi-stakeholder Challenges in Generation and Perspective: An Assessment Framework Interpretation of Evidence for Rare for Digital Health Solutions to Improve Disease Treatments Chronic Disease Management 09:25 - 10:40, Room 117 09:25 - 10:40, Room Virtual Karen Facey, United Kingdom Panos Kanavos, United Kingdom Eric Low, United Kingdom Madeleine Haig, United Kingdom Alfonso Iorio, Canada Charlie Nicholls, United Kingdom Anja Schiel, Norway Jean Mossman, United Kingdom Sheela Upadhyaya, United Kingdom Federico Augustovski, Argentina Alicia Granados, Spain 73

Radboud university medical centre Free download (CC BY-NC-ND 4.0) at — Department for Health Evidence www.radbouduniversitypress.nl and www.validatehta.eu Radboud university medical centre (Radboudumc), located ISBN 9789083178950 in Nijmegen, is one of the eight university hospitals in the DOI https://doi.org/10.54195/CKHB1659 Netherlands. It specializes in patient care, scientific research, teaching and training in order to have a significant impact on In the 2018-2021 EU Erasmus+ strategic partnerships project healthcare. “VALues In Doing Assessments of healthcare TEchnologies” (VALIDATE), a consortium of seven academic and HTA organ- The HTA group, part of the Department for Health Evidence, izations have developed an approach to HTA that allows for is internationally recognized for its excellent reputation in the integration of empirical analysis and normative inquiry. research and education in health sciences. The group has broad in-house knowledge and expertise about all aspects The VALIDATE handbook offers the reader an opportunity to related to HTA. get acquainted with the theoretical considerations and ap- prehend the associated practical and organizational implica- The activities are centered around the development of HTA tions of this approach. It offers those interested in HTA to reports, methodologies to improve decision-making pro- integrate empirical analysis and normative inquiry in a trans- cesses as well as improving the institutional HTA capacity in parent way. countries around the globe. Examples include the VALIDATE approach (see The VALIDATE handbook) and Evidence-Informed The handbook is endorsed by HTAi and EuroScan-iHTS. Deliberative Processes (EDP) for HTA. The EDP guide can be downloaded via: https://www.radboudumc.nl/en/research/ research-groups/global-health-priorities/our-products/prac- tical-guide/practical-guide. The research program of the HTA group serves as basis for academic teaching, training of Master and PhD students and those interested in HTA and global health. 74

Orals

ORALS Oral Presentations OP05 The Role of Conditional Reimbursement in the Lifecycle Monday, June 27, 2022 Approach OS01 Discrete Choice Speaker: Hedi Schelleman, Netherlands Experiments (DCE) OP06 Percutaneous Transforaminal Monday, June 27, 2022 - 12:10 - Endoscopic Discectomy: From 13:10, Room 114 Insufficient Evidence to Reimbursement OP01 Convergent Validity Between Discrete Choice Experiment and Other Speaker: Hedi Schelleman, Netherlands Stated Preference Methods: A Multi Study Comparison OS03 Economic Evaluations Speaker: Jorien Veldwijk, Netherlands Monday, June 27, 2022 - 12:10 - OP02 The Use of Discrete Choice 13:10, Room 215 Experiments for Measuring Patient Preferences in Health Technology OP08 Early Access to New Direct-acting Assessment Antiviral: A Journey on Introduction of Ravidasvir for Hepatitis C Treatment in Speaker: Michael Strauss, South Africa Malaysia OP03 Patient Characteristics Affect Their Speaker: Nazatul Syima Idrus, Malaysia Treatment Choice: A Discrete Choice Experiment With Breast Cancer Patients OP09 Cost-Effectiveness of in Six European Countries Laparoscopic Supracervical Hysterectomy Versus 2nd-Generation Speaker: Eugena Stamuli, United Endometrial Ablation for Treatment of Kingdom Heavy Menstrual Bleeding (The Health Trial) OS02 Early HTA Speaker: Rodolfo Hernández, United Monday, June 27, 2022 - 12:10 - Kingdom 13:10, Room 117 OP10 Outcomes of Expanded Access to OP04 Methodological Challenges of Transcatheter Aortic Valve Implantation Assessing an Evolving Technology: The in Ontario: A Model-Based Analysis Cochlear Implant for Deaf People Speaker: Rafael Miranda, Canada Speaker: Hugo Nijmeijer, Netherlands 76

ORALS OS04 European OP15 Improving the Osteoporosis Care Collaboration Trajectory by Collaboration Between Clinicians, Patients and Health Insurers Monday, June 27, 2022 - 12:10 - Within the Appropriate Care Program 13:10, Room 315 Speaker: Iris Groeneveld, Netherlands OP11 Differences and Similarities in Past Health Technology Assessments in OP16 Learning From Engagement Beneluxa Initiative Countries With Human Immunodeficiency Virus Community Organisations In The Health Speaker: Rick Vreman, Netherlands Technology Assessment Lifecycle OP12 Post-Launch Evidence Generation Speaker: Heidi Livingstone, United Among Health Technology Assessment Kingdom Bodies in Europe OS06 Systematic Reviews Speaker: Leonor Varela Lema, Spain for HTA OP13 EUnetHTA Relative Effectiveness Monday, June 27, 2022 - 12:10 - Assessments of Pharmaceutical and 13:10, Room 417 Other Technologies: Procedural Changes Implemented During Joint OP17 Robotic Versus Conventional Surgery: Action 3 An Overview of Systematic Reviews for Clinical Effectiveness with Quality Speaker: Sabine Ettinger, Austria Assessment of Current Evidence OS05 Patient and Speaker: Tzujung Lai, United Kingdom Clinician Involvement OP18 Clinical Effectiveness and Safety Monday, June 27, 2022 - 12:10 of Implantable Bulking Agents for Faecal - 13:10, Incontinence: A Systematic Review Beatrix Theatre Speaker: Lucia Gassner, Austria OP14 Involving People With a Lived Experience When Developing OP19 Comparative Effectiveness of a Proposed Health Technology Common Treatment Options for Benign Assessment of Pelvic Organ Prolapse Prostatic Hyperplasia: A Systematic Treatments Review and Network Meta-Analysis Speaker: Eugenie Johnson, United Speaker: Sirikan Rojanasarot, United Kingdom Kingdom 77

ORALS OS07 Quality of Evidence OS10 Artificial Intelligence Monday, June 27, 2022 - 12:10 - Monday, June 27, 2022 - 15:45 - 13:10, Virtual 16:45, Room 117 OP20 Is the Quality of Evidence in HTA O86 Chatbot-Based Symptom- Deteriorating Over Time?: A Case Study Checkers: A Systematic Review on Cancer Drugs in Australia Speaker: Reinhard Jeindl, Austria Speaker: Yuan Gao, Australia OP30 Model for Assessing the Value of OP21 A Critical Review of Existing AI in Medical Imaging (MAS-AI) Health Inequality and Health Inequity Frameworks in Evidence Synthesis Speaker: Iben Fasterholdt, Denmark Speaker: Patience Kunonga, United OP31 Assessment of AI Supported Kingdom Health Technologies - How to Move Forward? OP22 Using Threshold Analysis to Guide Searches for Additional Sources of Speaker: Signe Daugbjerg, Italy Evidence OS11 Horizon Scanning - Speaker: Sumayya Anwer, United Collaboration Kingdom Monday, June 27, 2022 - 15:45 OS09 HTA in World - 16:45, Beatrix Theatre Monday, June 27, 2022 - 15:45 - 16:45, Room 114 OP32 A Multi-Step Multi-Stakeholder Priority Setting Exercise for Faecal OP26 Policy Perspectives of Health Incontinence Technology Assessment in Ethiopia Speaker: Nicole O’connor, United Speaker: Desalegn Ararso, Ethiopia Kingdom OP27 Health Technology Assessment OP33 Expectations, Needs and Processes, Characteristics, and Key Challenges of Setting Up an differences in High, Middle, and Low- International Collaboration for Horizon income Countries of Asia Pacific Region Scanning of Medical Devices Speaker: Ashish Verma, India Speaker: Renee Else Michels, Netherlands OP28 Health Technology Assessment: A situation Analysis Of Zimbabwe Speaker: Blessing Dzingirai, Zimbabwe 78

ORALS OP34 Horizon Scanning a Matter OP39 The Real-Option Rate of Return of Collaboration. A Description of Approach to Inform the Pricing of the Processes of i-HTS Member Medicines Organisations Speaker: Simon van der Schans, The Speaker: Iñaki Gutierrez-ibarluzea, Netherlands Spain OP107 The Assessment Of The Price Of OS12 Life Cycle A Medicine: The Possible Application Of Cost-Based Pricing Methods Monday, June 27, 2022 - 15:45 - 16:45, Room 315 Speaker: Sibren Van Den Berg, The Netherlands OP35 Suitability of Preference Methods Across the Medical Product Lifecycle: A OS 14 Real World Data - Multi Criteria Decision Analysis Use Speaker: Jorien Veldwijk, Netherlands Monday, June 27, 2022 - 15:45 - 16:45, Virtual OP36 A Lifecycle Approach in Evaluating Medical Technologies: Insights from OP41 Facilitating Dialogue of RWE Use NICE’s Guidance Review Process in HTA: Taxonomy of Question/Data Source Pairings to Support a Registry of Speaker: Ivan Maslyankov, United Studies Kingdom Speaker: Ronald Akehurst, United OP37 Lifecycle Evaluation Models and Kingdom Frameworks Used to Assess Medical Devices: A Qualitative Evidence OP42 Increasing Access to Real World Synthesis Data to Move From Health Technology Assessment to Health Technology Speaker: Kathleen Harkin, Ireland Management OS13 Pricing Speaker: Shaun Rowark, United Kingdom Monday, June 27, 2022 - 15:45 - 16:45, Room 417 OP43 Conceptual and Methodological Factors Driving the Integration OP38 Managed (Early) Access in of Real-world Evidence in Drugs England: The ‘Ins And Outs’ and Technologies Reimbursement Appraisals Speaker: Charlotte Bee, United Kingdom Speaker: Geneviève Plamondon, Canada 79

ORALS OS15 Diabetes/Obesity OP49 A Systematic Review of the Activities of Early Advice, Early Dialogue, Monday, June 27, 2022 - 15:45 - Scientific Advice by HTA Doers 16:45, Virtual Speaker: Nora Ibargoyen-Roteta, Spain OP44 Does the Health Economic Modelling Structure Matter? An External Tuesday, June 28, 2022 Validation of Three Approaches Commonly Used in Obesity Modelling OS17 Children and Pediatrics Speaker: Bjoern Schwander, Germany Tuesday, June 28, 2022 - 09:50 - OP45 Screening Prediabetes Using 11:05, Room 114 1 hour Glucose. A Simulation Model to Estimate the Lifetime Health and OP50 Health Equity Considerations Economic Outcomes in HTA: A Case Example of Prenatal Screening Speaker: Martina Andellini, Italy Speaker: Beth Shaw, United States OP46 Assessing the Quality of Pharmacoeconomic Evaluations about OP51 Improving Childhood Cancer Type 2 Diabetes Mellitus Drugs in Management and Financing in Ghana: National Reimbursement Drug List Results From Stakeholder Mapping and Analysis Speaker: Yingyao Chen, China Speaker: Richmond Owusu, Ghana OS16 Multi Stakeholder Involvement OP52 Health Technology Assessment of Pain-Free Blood Draw Devices in Monday, June 27, 2022 - 15:45 - Pediatrics 16:45, Room 215 Speaker: Ilaria Cristiano, Italy OP47 Parallel Procedure Regulatory and Health Technology Assessment: OP53 Downstream Cost Savings Accelerating Access for Patients of Genome-Wide Sequencing for Childhood Developmental Disorders Speaker: Simone De Vries, Netherlands and Early-Onset Seizures: A Bench to Bedside Analysis OP48 Interactions Between Regulatory, HTA and Companies: A Multi- Speaker: Deirdre Weymann, Canada Stakeholder Survey on the Current Experiences and Future Landscape Evolvement Speaker: Tina Wang, United Kingdom 80

ORALS OS18 Horizon Scanning OP60 Methodological Guidance and Doctrine of the French National Tuesday, June 28, 2022 - 09:50 - Authority for Health for Economic 11:05, Room 117 Evaluation OP54 The Early Detection and Warning Speaker: Véronique Raimond, France System “SINTESIS-new technologies”: A Horizon Scanning Experience in Spain OP61 Developing a Core Dataset for the Economic Evaluation of Precision Speaker: Ana Isabel Hijas-Gómez, Spain Oncology: A Multi-Stage Approach to Enhanced Data Infrastructure OP55 Classification System for Innovative Medicines in the Pipeline: Speaker: Samantha Pollard, Canada New or Repurposed? OS20 Patient Speaker: Ross Fairbairn, United Kingdom Perspectives OP56 A Life Cycle Approach to Horizon Tuesday, June 28, 2022 - 09:50 Scanning Outputs - From Signals to - 11:05, Guidelines Beatrix Theatre Speaker: Sarah Khan, United Kingdom OP62 Patients’ Ppinion on Health Technology Assessment (HTA) Reports: OP57 The Identification of Technological An Analysis of Brazilian HTA in 2021 Innovations to Address the Challenge of Antimicrobial Resistance Using Horizon Speaker: Denis Satoshi Komoda, Brazil Scanning Approaches OP63 Patient and Public Perspectives Speaker: Lucy Barrass, United Kingdom on the Scottish Medicines Consortium Detailed Advice Document OS19 Guidance for HTA Speaker: Miranda Pierre, United Kingdom Tuesday, June 28, 2022 - 09:50 - 11:05, Room 215 OP64 NICE Listens: Engaging the Public on How to Address Health Inequalities OP59 The Tunisian Guidelines for in Health Technology Assessment and Pharmacoeconomic Analysis: What We Guideline Development Need to Know Speaker: Katherine Cresswell, United Speaker: Nabil Harzallah, Tunisia Kingdom OP65 An Overview of Participatory Approaches Used in the Development of Medical Devices: A Scoping Review Speaker: Kasper Woudstra, Netherlands 81

ORALS OS21 Treatment Value OP72 Software Tools for Systematic Literature Review in Medicine: A Review Tuesday, June 28, 2022 - 09:50 - and Feature Analysis 11:05, Room 417 Speaker: Kevin Kallmes, United States OP66 Low-Value Pharmaceutical Care Among Dutch General Practitioners: A OP73 Tools That Can Aid Adaptive Retrospective Cohort HTA to Ensure Rapid, Efficient, rend Pragmatic Priority Setting: A Scoping Speaker: Joris Muskens, Netherlands Review OP67 Considerations of Treatment Speaker: Lieke Fleur Heupink, Norway Novelty in Health Technology Assessment OS23 COVID Speaker: Patricia Synnott, United States Tuesday, June 28, 2022 - 09:50 - OP68 Real-World Experience with 11:05, Virtual NICE’s Willingness to Accept Less Costly, Less Effective Healthcare Technologies OP74 Assessing Public Confidence Towards COVID-19 Vaccines Through Speaker: Edel Falla, United Kingdom Social Media Insights Leveraged Using Artificial Intelligence Techniques OP69 Seeking A Better End - Development of a Healthcare Speaker: Kate Lanyi, United Kingdom Technology Data System Assessing Quality of In-Hospital End-of-Life Care OP76 “Thunderbirds Are Go!” Rapid Response HTA Outputs for COVID-19 Speaker: Elisa Neves, Brazil Speaker: Lirije Hyseni, United Kingdom OS22 HTA Tools OP77 Covidiagnostix: Health Technology Tuesday, June 28, 2022 - 09:50 - Assessment for Vaccination Strategy 11:05, Virtual Definition OP70 Gaps in the Evaluation of Clinical Speaker: Selenia Marino, Italy Decision Support Software (CDSS): Interviews with Australian Policymakers Speaker: Mah Laka, Australia OP71 PriTec Tool 2: Adaptation for Selection of Technologies to be Assessed for Inclusion into the Health Care System Speaker: Leonor Varela Lema, Spain 82

ORALS OS24 Environmental Impact OP83 Joining Efforts to Improve Patient Involvement in Health Technology Tuesday, June 28, 2022 - 09:50 - Assessment: The Case of the RedETS 11:05, Room 315 Patient Interest Group OP78 Taking a Societal Perspective Speaker: Yolanda Trinanes, Spain in Health Technology Assessment: Is Environmental Impact a Special Case? OP84 Cost Consequence Analysis: A Potential Framework to Incorporate Speaker: Juliet Kenny, United Kingdom Patient Preferences Into Health Technology Assessment and OP79 Incorporating Environmental Reimbursement Decisions Impacts into Health Technology Assessment: An Examination of Potential Speaker: Jennifer Whitty, United Approaches and Challenges Kingdom Speaker: Juliet Kenny, United Kingdom OS26 Decision Making OP80 ‘Green Metrics’ - Incorporating Tuesday, June 28, 2022 - 14:00 - Environmental Dimensions in Health 15:00, Room 117 Technology Assessment OP23 Managing Uncertainty in Precision Speaker: Tjerk Jan Schuitmaker- Oncology Decision-Making: Stakeholder Warnaar, Netherlands Perspectives and Recommendations for Improved Processes OP81 Do Sustainable Healthcare Principles Inform Guidance Speaker: Samantha Pollard, Canada Development?: An Exemplary Case Study in Respiratory Care OP07 Dealing with Uncertainty In Early Health Technology Assessment: An Speaker: Sarah Walpole, United Exploration of Methods For Decision Kingdom Making Under Deep Uncertainty OS25 Patient Involvement Speaker: Mirre Scholte, Netherlands Tuesday, June 28, 2022 - 14:00 OS27 Virtual - 15:00, Beatrix Theatre Tuesday, June 28, 2022 - 14:00 - 15:00, Room 215 OP82 Patient Involvement in Health Technology Assessment in OP88 Drawing Lines in The Sand: How Implementation Health Technology do we Define the Scope of Analysis in Assessment HTA and Economic Evaluation? Speaker: Lyazzat Kosherbayeva, Speaker: Marina Richardson, Canada Kazakhstan 83

ORALS OP89 The CE-Signal, a New Simplified OS29 PROMS HTA Method to Determine Whether Interventions are Cost-Effective Tuesday, June 28, 2022 - 14:00 - 15:00, Room 417 Speaker: Joost Enzing, Netherlands OP94 OPUF: A New Online Tool for OP90 Optimizing Health Technology Eliciting EQ-5D-5L Value Sets on the Assessment and Appraisal for Orphan Societal-, Group-, Subgroup-, and Drug Reimbursement: Experiences and Individual Person-Level Tools for Improvement Speaker: Paul Schnieder, Germany Speaker: Alessandra Blonda, Belgium OP95 Examining the Feasibility and OS28 Real World Data - Acceptability of Valuing the Lebanese Impact Version of the SF-6D using Standard Gamble Tuesday, June 28, 2022 - 14:00 - 15:00, Room 315 Speaker: Samer Kharroubi, Lebanon OP91 The Current State of Disease- OP96 Patient Reported Outcome Specific Registries for the Monitoring Measure-Select App of Expensive Pharmaceuticals in the Netherlands Speaker: Elise Quik, The Netherlands Speaker: Wim Goettsch, Netherlands OS30 Stakeholder Engagement OP92 Impact of Real-World Evidence on Health Technology Assessment and Tuesday, June 28, 2022 - 14:00 - National Guidance for Interventional 15:00, Room 114 Procedures: A UK Perspective OP97 Stakeholders’ Involvement in Speaker: Lakshmi Mandava, United Brazilian Health Technology Assessment Kingdom Incorporation (HTAi) in 2021: A Statistical Description of Demands to CONITEC OP93 Informing Efficient Diagnostic Monitoring Pathways Using Prospective Speaker: Denis Satoshi Komoda, Brazil Cohort Data: A Case Study in Neovascular Age-Related Macular OP87 Value From A Multi-stakeholder Degeneration Perspective: A Framework To Assess Digital Health Solutions For Improving Speaker: Graham Scotland, United Chronic Disease Management Kingdom Speaker: Madeleine Haig, United Kingdom 84

ORALS OP99 A Comparison of Three Methods for Multi-stakeholder Engagement: Focus Groups, Interviews, and Surveys Speaker: Kasper Woudstra, Netherlands OS32 Priority Setting Tuesday, June 28, 2022 - 14:00 - 15:00, Virtual OP103 Enhancing Legitimacy and Coherent Value Appraisal Across Interventions in Health Care and Social Services: The INESSS Strategy Speaker: Mireille Goetghebeur, Canada OP105 Gaps, Challenges and Priorities for Neurodegenerative Disease Research and Health Technology Assessment Speaker: Dalia Dawoud, United Kingdom OP100 Research ‘As’ Policy: Overview of Four Years Interactive Research of the Dutch Healthcare Institute on Medical Innovations Speaker: Payam Abrishami, Netherlands 85

Roche HTAi Symposium Monday, 27 June 2022 | 13.15 - 14.15 CEST Making Gene and Cell Therapies a Reality for Patients How HTA and Novel Payment Solutions Play a Central Role 86

Posters

POSTERS Poster Presentations Poster Presentations Session 1: Monday June 27, 10:25 – 10:35 COVID & Patient/Public/ PP89 Stimulating and Assuring Children Evidence Quality from a Dutch Funders’ Perspective – Introducing the ZonMw Poster Stand 4, Mies Reporting Checklist Bouwman Foyer Presenter: Wendy Rijmerink, PP10 Impact of Covid-19 on the Netherlands Management of Breast Cancer in Italy: The Perspectives of Patients and PP90 Startup and Inclusion Problems Coordinators in Healthcare Efficiency Studies, a Quantitative and Qualitative Analysis Presenter: Eugenio Di Brino, Italy Presenter: Karen van Liere-Visser, PP11 Impact of Qualitative Research in Netherlands the Spanish Network of HTA HTA Findings Presenter: Ana Toledo-Chávarri, Spain Poster Stand 5, Mies PP12 Challenges in Assessing the Bouwman Foyer Efficacy of Non-Pharmacological Measures in the Context of the Covid-19 PP59 Multidimensional Evaluation of Pandemic the Reducer Device in Patients with Refractory Angina Presenter: Lorena Aguilera-Cobos, Spain Presenter: Filippo Rumi, Italy Early & General Lifecycle PP60 Cost -Effectiveness Analysis of the SPRINTT Multicomponent Protocol Poster Stand 1, Mies Bouwman Foyer Presenter: Filippo Rumi, Italy PP01 Early HTA at work to ensure focus PP61 Plugging the Gap of Fetoscopy mechanisms to foster patient access in Congenital Diaphragmatic Hernia and understanding of medicinal product Pregnancies: Value for Money? information(ePI) Presenter: Jip Janssen, Netherlands Presenter: Eva Turk, Norway 88

POSTERS Lifecycle (Cost) Effectiveness PP09 Use of Real-World Evidence for Managing Health Technologies Poster Stand 2, Mies Throughout the Life Cycle of Bouwman Foyer Transcatheter Aortic Valve Interventions PP04 We Can Help People Who Feel Presenter: Catherine Truchon, Canada Lonely - A Systematic Review on Loneliness Interventions Poster Presentations Session 2: Monday June 27, 13:25 – 13:35 Presenter: Claus Loevschall, Denmark COVID & Patient/Public/ PP05 Effect Modifiers in Indirect Children Treatment Comparisons: Guidance Is Needed to Ensure an Unbiased Poster Stand 4, Mies Identification in Decision Making Bouwman Foyer Presenter: Andreas Freitag, United Kingdom PP25 Brazilian Collaborative Network for Covid-19 Modelling: Successful PP06 Clinical Effectiveness of Experience of Using Real-Time Science Fluticasone Furoate Nasal Spray for to Support Evidence-Based Decision Perennial Allergic Rhinitis in Children: A Making Systematic Re-View and Meta-Analysis Presenter: Michelle Rosa, Brazil Presenter: Paola Rivera, Peru PP26 Cost-Utility of Vaccination Against Lifecycle RWD & Quality Covid-19 In Brazil of Care & Disinvestment Presenter: Carlos Magliano, Brazil Poster Stand 3, Mies Bouwman Foyer PP27 Reusing and Adapting Health Technology Assessments (HTAs): An PP07 Improving the Use of Real-World Example From the COVID-19 Time Evidence in the Development of NICE Guidance Presenter: Maria-Jose Faraldo-Valles, Presenter: Seamus Kent, United Spain Kingdom PP08 Evaluation of Nutritional Status in Diabetic and Non-Diabetic Chronic Kidney Disease Patients Using a Web Tool Presenter: Ishfaq Rashid, India 89

POSTERS Early & General Lifecycle PP155 Impact of Parallel Submission On The Rollout Time and Poster Stand 1, Mies Health-Technology-Assessment Bouwman Foyer Recommendation of New-Active- Substances PP16 Machine Learning in the Treatment of Spinal Deformities: Early Life-cycle Presenter: Belen Sola, United Kingdom Economic Analysis in Australia Lifecycle (Cost) Presenter: Rashmi Joglekar, Australia Effectiveness PP17 Can Pritec Tool to be Useful in the Poster Stand 2, Mies Identification of Disruptive Healthcare Bouwman Foyer Technologies? PP19 Reimbursable Health Apps (DiGA) Presenter: Janet Puñal-Riobóo, Spain in Germany: Which Factors Impact the BfArM’s Assessment and Directory PP18 Horizon Scanning for Clinical Listing? – Updated Research Biosimilar Medicines: Informing the Lifecycle of Health Technology Presenter: Janika Drews, Germany Assessment and Market Access PP20 Effectiveness and Safety of Presenter: Amy Hussain, United Autogenic Training as a Clinical Kingdom Indication in Health Conditions HTA Findings Presenter: Ana Toledo-Chávarri, Spain Poster Stand 5, Mies PP21 Efficacy and Safety of Bouwman Foyer Aromatherapy: An Overview of Systematic Reviews PP153 The Economic and Fiscal Impact of Public Health Programs for Diabetic Presenter: Ana Toledo-Chávarri, Spain Patients in Italy Presenter: Eugenio Di Brino, Italy PP154 Associations of Orphan Designation and other Drug Development-Related Factors on the Rollout times and Health-Technology- Assessment Recommendations of New- Active-Substances Presenter: Belen Sola, United Kingdom 90

POSTERS Lifecycle RWD & Quality PP42 Impact of the COVID-19 Pandemic of Care & Disinvestment in the Brazilian National Committee Poster Stand 3, Mies for Health Technology Incorporation Bouwman Foyer (Conitec)’ Recommendation Process PP22 A Lifecycle Approach to the Use Presenter: Marilia Cardoso, Brazil of RWE in HTA Submissions and Re- Submissions, a Decade’s Experience PP145 Improving Patient Expert Involvement in the Lifecycle of Health Presenter: Dima Samaha, United Technology Assessments to Build Public Kingdom Confidence in Decision Making PP23 Lost in Translation? The Presenter: Heidi Livingstone, United Differences in the Use of Real-World States Evidence Across Key Markets Lifecycle (Cost) Presenter: Weiwei XU, Netherlands Effectiveness PP24 Organizing Outpatient Parenteral Poster Stand 2, Mies Antibiotic Therapy: Lessons from Bouwman Foyer Denmark PP35 Defecography (Evacuation Presenter: Claus Loevschall, Denmark Proctography) Poster Presentations Session 3: Presenter: Andrey Avdeyev, Kazakhstan Monday June 27, 13:40 – 13:50 PP36 Joint Replacement Under COVID & Patient/Public/ Computer Navigation and Robotic Children Systems Poster Stand 4, Mies Bouwman Foyer Presenter: Andrey Avdeyev, Kazakhstan PP41 COVID-19 Modelling to Support PP37 A Systematic Review of Machine Decision Making in Brazil: A Scoping Learning and Statistical Models for Review Predicting Coronary Heart Disease in Diabetic Patients Presenter: Michelle Rosa, Brazil Presenter: Li Jiu, Netherlands 91

POSTERS Lifecycle RWD & Quality Poster Presentations Session 4: of Care & Disinvestment Monday June 27, 13:55 – 14:05 Poster Stand 3, Mies COVID & Patient/Public/ Bouwman Foyer Children PP38 Does Changing the Specified Poster Stand 5, Mies Age of a Child Considered in EQ-5D-Y Bouwman Foyer Based Valuation Studies Affect Health Preferences? PP56 The Use of Computed Tomography for Detecting COVID-19 Presenter: Mark Oppe, Netherlands Pneumonia: Rapid Evidence Review PP39 Evidence Generation for Reimbursement of Digital Health Presenter: Samson Mideksa Legesse, Applications (DiGAs) in Germany Ethiopia Presenter: Naomi Fujita-Rohwerder, PP43 Impact of the COVID-19 Pandemic Germany on Scottish Medicine Consortium (SMC) Submission Characteristics, Acceptance PP40 Health Apps to Manage Rates, and Time to Advice Depression: Can we Separate the Grain from the Chaff? EvalDepApps Project Presenter: Guy Berg, United Kingdom Presenter: Carrion Carme, Spain Lifecycle (Cost) Effectiveness Oncology Poster Stand 2, Mies Poster Stand 1, Mies Bouwman Foyer Bouwman Foyer PP50 A Systematic Review of Cost- PP32 Assessment of Preferences Effectiveness Analysis of Screening for Treatment: A Discrete Choice Programs for Chronic Kidney Disease Experiment Among Italian Patients with Prostate Cancer Presenter: M. Rifqi Rokhman, Netherlands Presenter: Eugenio Di Brino, Italy PP51 Strengths and Limitations of PP33 Molecular Markers for the Migraine Management Guidelines in the Detection of Clinically Significant USA and Europe: A Targeted Literature Prostate Cancer Review Presenter: Tasmania Del Pino-sedeño, Presenter: Janet Ford, United States Spain 92

POSTERS PP52 Transcranial Magnetic Stimulation PP54 Harmonising the Process of for the Treatment of Cocaine Addiction: Developing Clinical Practice Guidelines A Systematic Review on Rare Diseases Across Europe: Training and Capacity Building Presenter: Ana Toledo-Chávarri, Spain Oncology Presenter: Juan Antonio Blasco-Amaro, Spain Poster Stand 1, Mies Bouwman Foyer PP55 Clinical Practice Guidelines Development in Rare Diseases Using PP47 Modelling Non-Small Cell Lung Health Technology Assessment: A Case Cancer Treatment: Predicted and Study of NKX2-1-Related Disorders Observed Impact of Immunotherapy in The Netherlands Presenter: Juan Antonio Blasco-Amaro, Spain Presenter: Zakile A Mfumbilwa, Netherlands Poster Presentations Session 5: Monday June 27, 16:55 – 17:05 PP48 A Micro-Costing Study for Circulating Tumor DNA Testing in Economic Evaluation Oncology Poster Stand 4, Mies Bouwman Foyer Presenter: Astrid Kramer, Netherlands PP44 The Cost-of-Illness of the PP62 Recommendations on Management of Patients Affected by Methodologies to Obtain Comparator Thyroid Nodules in the Italian Healthcare Efficacy in Health Economic Setting Assessments of Tumor-Agnostic Drugs Presenter: Michele Basile, Italy Presenter: Reva Efe, Netherlands PP45 The Cost-of-Illness of Diabetic Macular Edema in Italy Patient & Capacity Building Presenter: Michele Basile, Italy Poster Stand 3, Mies PP46 INEAS Guidelines for Bouwman Foyer Pharmacoeconomic Evaluation: Focus on HRQOL Recommendations PP53 Applying the Validate Approach to Frame the Assessment of Integrated Presenter: Nabil Harzallah, Tunisia Care Management in Aortic Valve Stenosis 93 Presenter: Laura Sampietro, Spain

POSTERS Lifecycle (Cost) PP71 Lessons Learned During Analyses Effectiveness of Appropriate Hearing Care: Building Bridges Between Patient Organisations, Poster Stand 2, Mies Health Professionals and Insurance Bouwman Foyer Companies PP66 Safety, Effectiveness and Cost- Presenter: Mariska Stam, Netherlands Effectiveness of Scalp Cooling Devices for the Prevention of Chemotherapy- Pricing & MEA Induced Alopecia Poster Stand 1, Mies Presenter: Tasmania Del Pino-Sedeño, Bouwman Foyer Spain PP13 Development of PP67 Implantable Holter Monitor with Recommendations and Proposal for a Link -Online- Technology for Prolonged Value-Based Managed Entry Agreement Cardiac Monitoring in Patients with for Italian Setting Previous Stroke Presenter: Filippo Rumi, Italy Presenter: Juan Antonio Blasco-Amaro, Spain PP14 Value-Based Pricing for Advanced Therapy Medicinal Products: Emerging PP68 DexcomG6® Device for Diabetes Affordability Solutions During Pregnancy Presenter: Elisabete Gonçalves, Portugal Presenter: Ana Toledo-Chávarri, Spain PP15 The National Pricing and Patient & Capacity Reimbursement Process in China, a Building 2021 Update Poster Stand 3, Mies Presenter: Xirong Song, United Bouwman Foyer Kingdom PP69 Supporting Decision Making: A Health Technology Assessment Training Proposal for Decision Makers Presenter: Maria-Jose Faraldo-Valles, Spain PP70 Enhancing HTA Processes in the Maltese System for Introducing New Medicines Presenter: Simone de Vries, Netherlands 94

POSTERS Poster Presentations Session 6: PP75 Incorporating Lifecycle Tuesday, June 28, Italy, 11:15 – Environmental Impact in the Economic 11:25 Evaluation of Health Technologies: Where Are We? Where Are We Going? COVID & Patient/Public/ Children Presenter: Carmen Guirado-Fuentes, Poster Stand 4, Mies Spain Bouwman Foyer PP76 Database on Evidence Based PP83 Economic Impact of Missed Telemedicine in a Hospital Setting Vaccinations on the Italian NHS Presenter: Ida Wagner Svendsen, Presenter: Eugenio Di Brino, Italy Denmark PP84 Change Management of Patient Economic Evaluation Associations in Italy: From Emergency Poster Stand 5, Mies Response to Organizational Learning Bouwman Foyer PP86 Gender-Neutral Human Presenter: Eugenio Di Brino, Italy Papilloma Virus Vaccination: More Than Cost-Effectiveness PP85 The Cost-Effectiveness of the Anti-COVID Vaccination Campaign in Presenter: Carmen Guirado-Fuentes, the Italian Healthcare Setting Spain Presenter: Michele Basile, Italy PP88 Bayesian Joint Models for Cost-Effectiveness Analyses Based Early & General Lifecycle on Clustered Participant Data, With Implementation in Stan Poster Stand 1, Mies Bouwman Foyer Presenter: Jonas Esser, Netherlands PP74 Taking a Lifecycle Approach to PP140 Economic Evaluation of Scottish Medicines Consortium Budget Several Vaccination Strategies Against Impact Analysis Rotavirus in Spain Presenter: Corinne Booth, United Presenter: Montserrat Carmona, Spain Kingdom 95

POSTERS Lifecycle (Cost) PP82 First Educational Trainings Effectiveness According to New Health Technology Poster Stand 2, Mies Assessment Guideline For Medicines in Bouwman Foyer Ukraine PP77 Safety, Effectiveness and Cost- Presenter: Oresta Piniazhko, Ukraine effectiveness of Telemedicine in Neurological Diseases Poster Presentations Session 7: Tuesday June 28, 13:10 – 13:20 Presenter: Ana Toledo-Chávarri, Spain Early & General Lifecycle PP78 Effectiveness and Safety of the Poster Stand 1, Mies FreeStyle Libre® Glucose Monitoring Bouwman Foyer System for T1DM in Childhood and Adolescence PP02 Is Glycated Hemoglobin a Valid Surrogate to Evaluate the Effectiveness Presenter: Ana Toledo-Chávarri, Spain of Drugs in Diabetes Mellitus Studies? PP79 Use of Vagus Nerve Stimulation Presenter: Paola Rivera, Peru Therapy in Treatment-Resistant Depression PP03 Early Assessment of Video Consultations in Rehabilitation After Presenter: Andrey Avdeyev, Kazakhstan Hand Injury Patient & Capacity Presenter: Linn Nathalie Stome, Norway Building Poster Stand 3, Mies HTA Findings Bouwman Foyer Poster Stand 4, Mies Bouwman Foyer PP143 International Assessment of the Health Care System in Kazakhstan. A PP98 Occupational Therapy for Adult Performance Analysis Persons With Cognitive Impairments: A Systematic Overview on Clinical Efficacy Presenter: Lyazzat Kosherbayeva, Kazakhstan Presenter: Petra Schnell-Inderst, Austria PP81 Barriers to Implementation of PP99 Innovating for Decreasing Health Technology Assessment Mortality and Resource use in Surgical Inpatient: The Zero Project Presenter: Lyazzat Kosherbayeva, Kazakhstan Presenter: Carla Fernandez Barcelo, Spain 96

POSTERS PP100 Improving the Assessment of PP97 Recommendations for Generating Effectiveness for Digital Applications South African Health-Related Quality of using B Statistic: Using WtsWrng as Life Data for Cost-Utility Analyses Case-Study Presenter: Sophia Emmarenzia Marsh, Presenter: Carla Fernandez Barcelo, United Kingdom Spain Poster Presentations Session 8: Lifecycle (Cost) Tuesday June 28, 13:25 – 13:35 Effectiveness HTA Methods Poster Stand 2, Mies Bouwman Foyer Poster Stand 4, Mies Bouwman Foyer PP101 Development Process of the Economic Guidelines in Tunisia PP114 Analysis of the Influence of Implicit Factors on HTA Deliberative Presenter: Nabil Harzallah, Tunisia Process: Results of a Survey in 5 European Countries PP102 Selecting the Sequence of Diagnostic Tests for Leprosy in Brazil Presenter: Clara Monleon, Switzerland Presenter: Bruno Barros, Brazil PP115 Analysis of Previous Joint Clinical Assessment and Potential Transferability Patient & Capacity to Four European Countries: Case Study Building and Conceptual Approach Poster Stand 3, Mies Presenter: Jeanne Kern, Switzerland Bouwman Foyer Lifecycle RWD & Quality PP95 Health Professionals’ Participation of Care & Disinvestment on Health Technology Assessment (HTA) Public Consultation: A Distribution Poster Stand 5, Mies Analysis of Brazilian HTA in 2021 Bouwman Foyer Presenter: Denis Satoshi Komoda, Brazil PP117 Larger Impact of an Appropriate Care Program by Involving Health Care PP96 Joint Clinical Assessments – Professionals; A Case Report on Cervical Implementation and Lessons for the Pre-malignancy Next Stage of EU HTA Presenter: Thom de Bruijin, Netherlands Presenter: Dima Samaha, United Kingdom 97

POSTERS PP118 Cyclic Mental Health Technology Pricing & MEA Assessment; Priority Setting and Involving Stakeholders; A Case Report Poster Stand 3, Mies from the Netherlands Bouwman Foyer Presenter: Koen Böcker, Netherlands PP111 Reimbursement and Payment Models: A Survey of Stakeholders’ PP119 Results and Lessons Learned from Current Experiences and Future Outlook the Cyclic Appropriate Care Program Within the Dutch Policy Setting from National Health Care Institute of the Netherlands Presenter: Marcelien Callenbach, Netherlands Presenter: Hedy Maagdenberg, Netherlands PP112 Reimbursement Decisions for Medical Services in Austria: An Analysis Oncology of Influencing Factors for the Hospital Individual Services Catalogue Poster Stand 1, Mies Bouwman Foyer Presenter: Gregor Goetz, Austria PP120 Fluorescent in Situ Hybridization PP113 Reimbursement of Oncology (FISH) vs Conventional Cytogenetic Therapies with Limited Clinical Evidence (CC) for Detecting High-Risk Genetic in the Netherlands Mutations in Multiple Myeloma Presenter: David Smalbrugge, Presenter: Denis Satoshi Komoda, Brazil Netherlands PP121 High Dose Chemotherapy or Poster Presentations Session 9: Standard of Care for BRCA1-like Stage Tuesday June 28, 13:40 – 13:50 III Breast Cancer Patients: A Discrete Choice Experiment Lifecycle (cost) effectiveness Presenter: Joost Verbeek, Netherlands Poster Stand 2, Mies PP122 MR-guided HIFU for Non-Surgical Bouwman Foyer Treatment of Prostate Cancer, Uterine Fibroids, Adenomyosis and Pain in Bone PP123 Fair Drug Pricing: Review of Metastases Literature and Models Presenter: Andrey Avdeyev, Kazakhstan Presenter: Olena Wagner, Ukraine 98

POSTERS PP125 Economic Evaluation of Other Molecular Diagnostics –A Review and Poster Stand 1, Mies Future Directions Bouwman Foyer Presenter: Janet Bouttell, United PP138 Heuristics and the Decision to Kingdom Share Health Data: A Qualitative Study PP108 Multidimensional Analysis of Presenter: Anna Hermansen, Canada Peristeen Plus Medical Device PP103 Early HTA of integrated care to Presenter: Filippo Rumi, Italy increase employment for persons with substance use disorder Lifecycle RWD & Quality of Care & Disinvestment Presenter: Linn Nathalie Stome, Norway Poster Stand 5, Mies PP34 NGS for Informing Lung Cancer Bouwman Foyer Therapy in Europe – Hospital Impact with a Lifecycle Perspective PP132 Disinvestment Initiatives in Healthcare: A Scoping Review Of Presenter: Rhodri Saunders, Germany Systematic Reviews Patient & Capacity Presenter: Hanin Kamaruzaman, United Building Kingdom Poster Stand 3, Mies Bouwman Foyer PP133 Cost Spent on Early Discontinuation of Treatment with Anti- PP126 Direct Patient Involvement in cancer Medication in the Netherlands HTA in Canada and Brazil: The Patients Perspectives Presenter: Rick Vreman, Netherlands Presenter: Aline Silveira Silva, Canada PP134 Health Technology Assessment Life Cycle Approach in Asthma Care PP127 Impact of Brazilian Patient Testimonials on Medical Devices and Presenter: Geert van Kemenade, Public Confidence in the Healthcare Netherlands Decision-Making Presenter: Aline Silveira Silva, Canada PP128 Development and Piloting of an Online Training Course on Health Technology Assessment for Patients Presenter: Yolanda Triñanes, Spain 99

POSTERS Pricing & MEA PP147 Conditional Reimbursement of Medicinal Products, A Procedure Poster Stand 4, Mies for Orphan Drugs, Conditionals and Bouwman Foyer Exceptionals PP129 Usefulness, Acceptability and Presenter: Floor Van Heesch, Satisfaction of a Decision-Making Tool Netherlands for Clinical Meso-Management in Type 2 Diabetes Mellitus PP148 The Impact of Health Technology Wales Guidance for Presenter: Ana Toledo-Chávarri, Spain Autologous Haematopoietic Stem Cell Transplantation: Two Years Post- PP130 Fair Pricing Models for Innovative Publication Orphan Medicines: A Case Study Presenter: Lauren Elston, United Presenter: Noa Rosenberg, Netherlands Kingdom PP131 European Market Access Patient & Capacity Landscape Analysis of Reimbursement Building Drivers in Pompe Disease: Results from 26 Payer Interviews Poster Stand 3, Mies Bouwman Foyer Presenter: Alasdair Macculloch, United Kingdom PP149 A Multidimensional and Multistakeholder Approach: Assessing Poster Presentations Session 10: ELSI+ for Telemedicine in Neurological Tuesday June 28, 16:35 – 16:45 Diseases Economic Evaluation Presenter: Ana Toledo-Chávarri, Spain Poster Stand 4, Mies PP150 The Role of Expert Consensus Bouwman Foyer in UK Guidance: Patient Selection for Hydrogel Spacer Use During Prostate PP146 The Use of Indirect Comparisons Cancer Radiotherapy for Reimbursement Decision Making in the Netherlands and England Presenter: Emily Woodward, Switzerland Presenter: Rachel Kalf, Netherlands PP151 VALIDATE Methodology on a Medication Related Clinical Decision Support System: Holistic Assessment for Optimal Technology Adoption Presenter: Carla Fernandez Barcelo, Spain 100